Zentalis Q2 2026 cash $174.6M; DENALI Part 2 topline readout expected 1H 2027

Zentalis Pharmaceuticals, Inc.

2026-Q2 EPS reported -$1.10

Cash, cash equivalents and marketable securities of $174.6M as of June 30, 2026, providing runway into late 2027.
R&D expenses $35.2M (up $7.6M YoY) driven by $7.0M milestone payment for ASPENOVA Phase 3 start and increased clinical costs.
Total operating expenses $44.4M for Q2 2026 vs $36.1M in Q2 2025.
FDA Type D meeting: no objection to azenosertib 400mg QD 5:2 dose for Cyclin E1-positive PROC; accelerated approval strategy intact.
DENALI Part 2 enrollment complete in Parts 2a/2b; Part 2c enrolling; integrated topline readout expected 1H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.